Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaceutical and medical device company Angiotech has received a favorable decision from the Intellectual Property Office of New Zealand.
Subscribe to our email newsletter
Johnson & Johnson’s subsidiary, Conor Medsystems, had attempted to revoke Angiotech’s New Zealand patent 523799, which pertains to compositions comprising a polymer and paclitaxel, as well as paclitaxel-eluting stents.
William Hunter, president and CEO of Angiotech, said: “Consistent with virtually all international rulings to date, this decision further corroborates the strength of company intellectual property and ability to defend global patent portfolio.”